

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Brii Biosciences Limited
騰盛博藥生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2137)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO
THE ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2022**

Reference is made to the annual report of Brii Biosciences Limited (the “**Company**”) for the year ended December 31, 2022 published on April 27, 2023 (the “**2022 Annual Report**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the 2022 Annual Report.

In addition to the disclosures under the section headed “Share Incentive Schemes” in the Report of Directors and note 25 to the consolidated financial statements as set out in the 2022 Annual Report, the Company would like to provide the following additional information in relation to the Share Incentive Schemes pursuant to Rules 17.09(3) of the Listing Rules:

- (a) the total number of Shares available for issue under the Pre-IPO Share Incentive Plan was 21,036,868 Shares, representing approximately 2.89% of the issued Shares as at the date of the 2022 Annual Report;
- (b) the total number of Shares available for issue under the Post-IPO Share Option Scheme (including the options granted but not yet exercised and the options available for future grants) was 69,792,092 Shares, representing approximately 9.59% of the issued Shares as at the date of the 2022 Annual Report; and
- (c) the total number of Shares available for issue under the Post-IPO Share Award Scheme (including the share awards granted but unvested and the share awards available for future grants) was 34,384,784 Shares, representing approximately 4.73% of the issued Shares as at the date of the 2022 Annual Report.

The above additional information does not affect other information contained in the 2022 Annual Report. Save as disclosed above, all other information in the 2022 Annual Report remains unchanged.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, August 21, 2023

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Dr. Ankang Li as executive directors; Mr. Robert Taylor Nelsen as non-executive director; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive directors.